Catalio Capital Management

Catalio Capital Management is an SEC-registered investment adviser (CRD 310374, SEC file 801-121976) that describes itself as focused on the full lifecycle of innovative healthcare investing, across private, public and credit markets. It runs four stated strategies: Private Equity and Venture Capital, investing in privately held innovative healthcare companies at all stages from inception to IPO; Structured Opportunities, providing senior-secured financing to healthcare innovators; Public Equities, a fundamental equity long/short strategy investing in global healthcare equities across innovative drugs, devices, diagnostics and data; and Co-Investments offering limited partners direct access to selected deals. The firm operates from New York, Washington DC and London, and states that it works with a network of more than 45 Venture Partners who hold equity interests across all Catalio strategies. It is a multi-strategy healthcare investment manager rather than a pure venture partnership.

$2B (the homepage prints "$2B In assets under management *as of 10/01/2025"; the raw date form is carried here because for a US filer 10/01/2025 reads as 1 October 2025) AUM 82/100 Power Score™ 2020 Founded New York, NY
Healthcare Biotech Medical Devices Diagnostics Life Sciences Data
View Live Interactive Profile → Visit Catalio Capital Management's Website ↗

Signature Exit

Hyperfine (Nasdaq: HYPR), which became publicly traded through HealthCor Catalio Acquisition Corp. (Nasdaq: HCAQ), the special purpose acquisition company of which Catalio co-founder George Petrocheilos was President; the SPAC and Hyperfine share SEC CIK 0001833769.

Key Partners & Leadership

Co-Founder & Managing Partner
Co-Founder & Managing Partner
Partner & Head of Credit
Partner & Head of Operations
Partner & Head of Public Equities
Partner & Head of Research
Partner
Partner
Partner
Partner

Firm Timeline

2020
Catalio Capital Management is founded, per the firm's own July 2025 fund announcement, which describes Catalio as 'founded in 2020'.
2021
Catalio Capital Management, LP is approved as an SEC-registered investment adviser with effect from 30 July 2021 (SEC file 801-121976, CRD 310374).
2022
Catalio closes its third life sciences fund at $381 million on 2 May 2022.
2022
Chau Khuong joins Catalio as General Partner, announced 25 May 2022. He is not listed on the firm's team page as of 7 September 2026.
2025
Catalio Nexus Fund IV closes with over $400 million in commitments including co-investment vehicles, announced 1 July 2025, at which point the firm states $2 billion across private equity, private credit and public equities.
2026
Catalio Structured Opportunities Fund II closes with more than $325 million in commitments, announced 7 January 2026; the strategy is stated to have completed 21 investments to date.
2026
Catalio files a Form 13F-HR for the quarter ended 30 June 2026 reporting 39 positions with a total value of $532,102,416.

Notable Public Portfolio Companies